Home/Pipeline/CK-136

CK-136

Heart Failure

Phase 1ActiveNCT

Key Facts

Indication

Heart Failure

Phase

Phase 1

Status

Active

Company

Cytokinetics

About Cytokinetics

Cytokinetics' mission is to develop innovative medicines that improve the healthspan of patients suffering from cardiovascular and neuromuscular diseases characterized by compromised muscle function. Its key achievement is the 2025 FDA approval of MYQORZO (aficamten), a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM), validating its decades-long focus on sarcomere biology. The company's strategy is to build a leading muscle-focused specialty biopharma business by commercializing aficamten across HCM subtypes, advancing late-stage candidates in heart failure, and leveraging its platform to develop treatments for neuromuscular conditions like ALS.

View full company profile

Therapeutic Areas

Cardiovascular Neuromuscular

Other Heart Failure Drugs

Drug	Company	Phase	Status
Cardiac Cell Therapy Program	StemCardia	Pre-clinical	Active
NTP42	ATXA Therapeutics	Preclinical	Platform potential identified
Heart Failure Trial	Clinical Investigation Specialists	Not Specified	Actively Recruiting
INPEFA (sotagliflozin)	Lexicon Pharmaceuticals	Approved	Commercial
MyCardia™	Avery Therapeutics	Pre-clinical	Active
Cardiac Assist Device	Second Heart Assist	Pre-clinical	Active
Isosorbide Dinitrate/Hydralazine HCl Tablets	i3 Pharmaceuticals	Approved	Active
TLT-101	TikkunLev Therapeutics	Pre-clinical	Active
Undisclosed Heart Regeneration Program	Animatus Biosciences	Pre-clinical	Active
AFteR Registry	Occlutech	N/A (Registry)	Active
biotx.ai Target Discovery Collaboration	HeartBeat.bio	Pre-clinical	Active
Surlorian	RyCarma Therapeutics	Phase 2	Active